5results about How to "Regulate lipid metabolism" patented technology

This invention relates to a lipid-lowering synbiotic, its preparation method, and its application, belonging to the field of egg-laying hen farming technology. The lipid-lowering synbiotic of this invention comprises the following components in parts by weight: 3-85 parts of traditional Chinese medicine extract, 1-25 parts of probiotics, 3-30 parts of prebiotics, 1-16 parts of enzyme preparation, and 4-55 parts of dietary therapy components. This synbiotic not only significantly improves the lipid metabolism of laying hens but also significantly prolongs the peak egg-laying period, increases the egg production rate, reduces cholesterol content in egg yolks, promotes calcium and phosphorus absorption, and reduces the paralysis rate in laying hens. It comprehensively improves the economic benefits of egg-laying hen farming.

The application discloses Luzhou-flavor liquor dreg water-soluble glucose oligosaccharide and a preparation method and application thereof, and belongs to the technical field of medicines.The application extracts water-soluble glucose oligosaccharide from Luzhou-flavor liquor dreg as raw material.The main chain of the Luzhou-flavor liquor dreg water-soluble glucose oligosaccharide is composed of glucose, and the side chain comprises arabinose and glucose; the Luzhou-flavor liquor dreg water-soluble glucose oligosaccharide is composed of arabinose, galactose, glucose and xylose, and the molar ratio is 8.81:2.54:76.82:6.90.The water-soluble glucose oligosaccharide prepared by the application can obviously improve the symptoms of alcoholic liver, and has the effects of inhibiting liver damage and improving the activity of liver antioxidant enzymes.In addition, the Luzhou-flavor dreg in the application is a by-product of liquor fermentation, has high raw material yield and low cost, and the application can improve the resource utilization value of the dreg.

The invention discloses a novel application of ginseng, poria cocos and atractylodes macrocephala koidz powder polysaccharide in improving obesity type 2 diabetes mellitus (T2DM), relates to a pharmacological action of the ginseng, poria cocos and atractylodes macrocephala koidz powder polysaccharide in improving obesity T2DM and application of the ginseng, poria cocos and atractylodes macrocephala koidz powder polysaccharide, in particular to preparation of the ginseng, poria cocos and atractylodes macrocephala koidz powder polysaccharide and application of the ginseng, poria cocos and atractylodes macrocephala koidz powder polysaccharide in medicines and health foods for treating obesity T2DM, and belongs to the technical field of traditional Chinese medicines. The ginseng, poria cocos and atractylodes macrocephala koidz powder polysaccharide is extracted, and pharmacological experiments prove that the ginseng, poria cocos and atractylodes macrocephala koidz powder polysaccharide has a relatively strong effect of improving obesity T2DM. The ginseng, poria cocos and atractylodes macrocephala koidz powder polysaccharide disclosed by the invention has relatively good activity in the aspect of improving the obesity T2DM function, small side effects, low price and relatively good druggability, and can be used for preparing medicines for improving the obesity T2DM function independently or in combination with other medicines. The compound can be prepared into granules, capsules, tablets and other dosage forms with pharmaceutically or food acceptable carriers or excipients.

This invention relates to the field of biopharmaceutical technology, and in particular to an antibody-targeted modified dual-strain prebiotic delivery system, its preparation method, and its applications. This invention modifies VCAM-1 antibody fragments onto *AKK* bacteria and *Bifidobacterium lactis* Probio-M8, then utilizes fructooligosaccharides and inulin as prebiotics to enhance probiotic metabolism and promote intestinal colonization. Finally, it coats the system with hydroxypropyl methylcellulose phthalate (HPMCP) enteric coating to construct the antibody-targeted modified dual-strain prebiotic delivery system—V-PM8-Am-FI-HPMC. The V-PM8-Am-FI-HPMC provided by this invention can simultaneously achieve intestinal flora regulation, lipid metabolism balance, inflammation suppression, ischemia improvement, and vascular anti-calcification, ultimately achieving the purpose of treating and / or improving atherosclerosis, while ensuring targeting and safety.

The application provides an effect and application of CREPT in fatty liver disease and complications thereof, in particular, application of CREPT gene or protein as a target or a reagent for targeting the CREPT gene or protein in treatment of metabolic-related fatty liver disease and fatty liver disease complications or in preparation of a medicine for treating metabolic-related fatty liver disease and fatty liver disease complications, and the metabolic-related fatty liver disease and fatty liver disease complications are treated by reducing the expression of the CREPT gene or reducing the function or inactivating the CREPT protein. The present application firstly finds that the CREPT is closely related to the metabolic-related fatty liver disease: the systemic or local medication can effectively treat the metabolic-related fatty liver disease and fatty liver disease complications by reducing the expression of the CREPT.